Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,173 questions in 89 reviews · Neuromuscular
current versionsNo studies 302 · 25.7%Ungraded 119 · 10.1%Very low 267 · 22.8%Low 239 · 20.4%Moderate 177 · 15.1%High 69 · 5.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Carbamazepine vs placebo Rescue analgesic consumption · patients with pain in Guillain‐Barré syndrome Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane | no estimate extracted | 1 study · 24 participants | Very low |
Methylprednisolone vs placebo Number of patients with self reported pain relief of 50% or greater (not measured) · patients with Guillain‐Barré syndrome, with varying severities of pain Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane | no estimate extracted | NR | No studies |
Methylprednisolone vs placebo Number of participants with pain after 4 weeks · patients with Guillain‐Barré syndrome, with varying severities of pain Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane | RR 0.89 [0.68, 1.16] | 1 study · 223 participants | Low |
Methylprednisolone vs placebo Number of participants with decreased pain after 4 weeks · patients with Guillain‐Barré syndrome, with varying severities of pain Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane | RR 0.95 [0.63, 1.42] | 1 study · 223 participants | Low |
Methylprednisolone vs placebo Number of participants with increased pain after 4 weeks · patients with Guillain‐Barré syndrome, with varying severities of pain Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane | RR 0.85 [0.52, 1.41] | 1 study · 223 participants | Low |
Gabapentin vs carbamazepine Number of patients with self reported pain relief of 50% or greater (not measured) · intensive care unit in India Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane | no estimate extracted | NR | No studies |
Gabapentin vs carbamazepine Pain score (numerical rating scale of 0 to 10: 0 = no pain, 10 = worst pain) · intensive care unit in India Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane | no estimate extracted | 24 participants | Very low |
Gabapentin vs carbamazepine Sedation score (numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) · intensive care unit in India Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane | no estimate extracted | 24 participants | Very low |
Gabapentin vs carbamazepine Rescue analgesic consumption · intensive care unit in India Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane | no estimate extracted | 24 participants | Very low |
Gabapentin vs placebo Pain score (numerical rating scale of 0 to 10: 0 = no pain, 10 = worst pain) · patients with pain in Guillain‐Barré syndrome Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane | no estimate extracted | 2 studies · 54 participants | Very low |
Gabapentin vs placebo Sedation score (numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) · patients with pain in Guillain‐Barré syndrome Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane | no estimate extracted | 2 studies · 54 participants | Very low |
Gabapentin vs placebo Rescue analgesic consumption · patients with pain in Guillain‐Barré syndrome Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane | no estimate extracted | 2 studies · 54 participants | Very low |
Gabapentin vs placebo Nausea · patients with pain in Guillain‐Barré syndrome Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane | RR 0.5 [0.05, 5.04] | 1 study · 18 participants | Very low |
Gabapentin vs placebo Constipation · patients with pain in Guillain‐Barré syndrome Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane | RR 0.14 [0.01, 2.54] | 1 study · 18 participants | Very low |
Carbamazepine vs placebo Number of patients with self reported pain relief of 50% or greater (not measured) · patients with pain in Guillain‐Barré syndrome Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane | no estimate extracted | NR | No studies |
Carbamazepine vs placebo Pain score (numerical rating scale of 0 to 10: 0 = no pain, 10 = worst pain) · patients with pain in Guillain‐Barré syndrome Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane | no estimate extracted | 1 study · 24 participants | Very low |
Carbamazepine vs placebo Sedation score (numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) · patients with pain in Guillain‐Barré syndrome Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane | no estimate extracted | 1 study · 24 participants | Very low |
Intervention NR Impairment ‐ change in CMTNS at 24 months (0 to 36 points) · adults with CMT1A Ascorbic acid for the treatment of Charcot‐Marie‐Tooth disease (2015) · Cochrane | no estimate extracted | 3 studies · 388 participants | High |
Intervention NR Impairment ‐ change in CMTES at 24 months (0 to 28 points) · adults with CMT1A Ascorbic acid for the treatment of Charcot‐Marie‐Tooth disease (2015) · Cochrane | no estimate extracted | 2 studies · 337 participants | Moderate |
Intervention NR Change in timed 10‐m walk at 12 months (seconds (s)) · adults with CMT1A Ascorbic acid for the treatment of Charcot‐Marie‐Tooth disease (2015) · Cochrane | no estimate extracted | 3 studies · 401 participants | High |
Intervention NR Change in foot dorsiflexion at 12 months (N) · adults with CMT1A Ascorbic acid for the treatment of Charcot‐Marie‐Tooth disease (2015) · Cochrane | no estimate extracted | 4 studies · 423 participants | High |
Intervention NR Change in 9‐hole peg test (HPT) at 12 months (seconds) · adults with CMT1A Ascorbic acid for the treatment of Charcot‐Marie‐Tooth disease (2015) · Cochrane | no estimate extracted | 3 studies · 286 participants | Moderate |
Intervention NR Serious adverse events (SAE; %) · adults with CMT1A Ascorbic acid for the treatment of Charcot‐Marie‐Tooth disease (2015) · Cochrane | no estimate extracted | 1 study · 702 participants | High |
Nocturnal ventilation vs no ventilation Mortality at 1 year (or more) · patients with neuromuscular and chest wall disorders and chronic hypoventilation Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall… (2014) · Cochrane | RR 0.62 [0.42, 0.91] | 4 studies · 99 participants | Very low |
Nocturnal ventilation vs no ventilation Unplanned admission to hospital · patients with neuromuscular and chest wall disorders and chronic hypoventilation Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall… (2014) · Cochrane | RR 0.25 [0.08, 0.82] | 2 studies · 38 participants | Very low |
Nocturnal ventilation vs no ventilation No improvement of hypoventilation symptoms: long‐term · patients with neuromuscular and chest wall disorders and chronic hypoventilation Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall… (2014) · Cochrane | RR 0.43 [0.18, 1.03] | 3 studies · 51 participants | Very low |
Nocturnal ventilation vs no ventilation No improvement of daytime hypercapnia: long‐term · patients with neuromuscular and chest wall disorders and chronic hypoventilation Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall… (2014) · Cochrane | RR 0.59 [0.41, 0.86] | 3 studies · 58 participants | Very low |
Volume‐cycled ventilation vs pressure‐cycled ventilation Mortality at 1 year (or more) Not measured ‐ data reported for mortality at 3 months · patients with neuromuscular and chest wall disorders and chronic hypoventilation Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall… (2014) · Cochrane | RR 1.29 [0.1, 17.14] | 1 study · 16 participants | Very low |
Volume‐cycled ventilation vs pressure‐cycled ventilation Unplanned admission to hospital ‐ not measured · patients with neuromuscular and chest wall disorders and chronic hypoventilation Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall… (2014) · Cochrane | no estimate extracted | NR | No studies |
Volume‐cycled ventilation vs pressure‐cycled ventilation No improvement of hypoventilation symptoms: long‐term ‐ not measured · patients with neuromuscular and chest wall disorders and chronic hypoventilation Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall… (2014) · Cochrane | no estimate extracted | NR | No studies |
Volume‐cycled ventilation vs pressure‐cycled ventilation No improvement of daytime hypercapnia: long‐term ‐ not measured · patients with neuromuscular and chest wall disorders and chronic hypoventilation Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall… (2014) · Cochrane | no estimate extracted | NR | No studies |
IVIg vs PE Change in disability grade 4 weeks after randomisation · patients with Guillain‐Barré syndrome Intravenous immunoglobulin for Guillain‐Barré syndrome (2014) · Cochrane | no estimate extracted | 5 studies · 536 participants | Moderate |
IVIg vs PE Number improved by 1 or more disability grades after 4 weeks · patients with Guillain‐Barré syndrome Intravenous immunoglobulin for Guillain‐Barré syndrome (2014) · Cochrane | RR 1.08 [0.94, 1.23] | 6 studies · 567 participants | Moderate |
IVIg vs PE Dead or disabled after 12 months (48 weeks) · patients with Guillain‐Barré syndrome Intravenous immunoglobulin for Guillain‐Barré syndrome (2014) · Cochrane | RR 0.98 [0.55, 1.72] | 1 study · 243 participants | Low |
IVIg vs PE Relapse or treatment‐related fluctuation · patients with Guillain‐Barré syndrome Intravenous immunoglobulin for Guillain‐Barré syndrome (2014) · Cochrane | RR 0.89 [0.42, 1.89] | 3 studies · 445 participants | Low |
IVIg vs PE Participants in whom treatment was discontinued · patients with Guillain‐Barré syndrome Intravenous immunoglobulin for Guillain‐Barré syndrome (2014) · Cochrane | RR 0.14 [0.05, 0.36] | 4 studies · 498 participants | High |
IVIg vs PE Number of participants with adverse events attributed to treatment · patients with Guillain‐Barré syndrome Intravenous immunoglobulin for Guillain‐Barré syndrome (2014) · Cochrane | RR 0.84 [0.54, 1.3] | 4 studies · 388 participants | Moderate |
Intensive insulin therapy vs conventional insulin therapy Occurrence of CIP/CIM ‐ in total population randomised · critically ill patients Interventions for preventing critical illness polyneuropathy and critical illness myopathy (2014) · Cochrane | RR 0.7 [0.6, 0.82] | 2 studies · 2748 participants | Low |
Corticosteroids vs placebo compared Death ‐ death at 180 days in total population randomised · critically ill patients Interventions for preventing critical illness polyneuropathy and critical illness myopathy (2014) · Cochrane | RR 0.99 [0.64, 1.52] | 1 study · 180 participants | High |
Corticosteroids vs placebo compared Serious adverse events (dichotomous data) ‐ shock · critically ill patients Interventions for preventing critical illness polyneuropathy and critical illness myopathy (2014) · Cochrane | RR 0.41 [0.17, 1.01] | 1 study · 180 participants | High |
Corticosteroids vs placebo compared Serious adverse events (dichotomous data) ‐ serious infection · critically ill patients Interventions for preventing critical illness polyneuropathy and critical illness myopathy (2014) · Cochrane | RR 0.68 [0.42, 1.11] | 1 study · 180 participants | High |
Corticosteroids vs placebo compared Serious adverse events (dichotomous data) ‐ suspected or probable pneumonia · critically ill patients Interventions for preventing critical illness polyneuropathy and critical illness myopathy (2014) · Cochrane | RR 0.44 [0.18, 1.09] | 1 study · 180 participants | High |
Corticosteroids vs placebo compared Serious adverse events (continuous data) ‐ blood glucose (mg/dL) on day 7 · critically ill patients Interventions for preventing critical illness polyneuropathy and critical illness myopathy (2014) · Cochrane | no estimate extracted | 1 study · 180 participants | High |
Early physical therapy vs control Occurrence of CIP/CIM ‐ in the total population randomised · critically ill patients Interventions for preventing critical illness polyneuropathy and critical illness myopathy (2014) · Cochrane | RR 0.81 [0.6, 1.08] | 1 study · 104 participants | Low |
Early physical therapy vs control Occurrence of CIP/CIM ‐ in screened population · critically ill patients Interventions for preventing critical illness polyneuropathy and critical illness myopathy (2014) · Cochrane | RR 0.62 [0.39, 0.96] | 1 study · 82 participants | Moderate |
Early physical therapy vs control Serious adverse events ‐ in total population randomised · critically ill patients Interventions for preventing critical illness polyneuropathy and critical illness myopathy (2014) · Cochrane | RR 3.36 [0.14, 80.62] | 1 study · 104 participants | Moderate |
Electrical muscle stimulation vs control Occurrence of CIP/CIM ‐ in the total population randomised · critically ill patients Interventions for preventing critical illness polyneuropathy and critical illness myopathy (2014) · Cochrane | RR 0.94 [0.78, 1.15] | 1 study · 140 participants | Very low |
Electrical muscle stimulation vs control Occurrence of CIP/CIM ‐ in screened population · critically ill patients Interventions for preventing critical illness polyneuropathy and critical illness myopathy (2014) · Cochrane | RR 0.32 [0.1, 1.01] | 1 study · 52 participants | Very low |
Intensive insulin therapy vs conventional insulin therapy Occurrence of CIP/CIM ‐ in screened population · critically ill patients Interventions for preventing critical illness polyneuropathy and critical illness myopathy (2014) · Cochrane | RR 0.65 [0.55, 0.77] | 2 studies · 825 participants | Moderate |
Intensive insulin therapy vs conventional insulin therapy Duration of mechanical ventilation ‐ in total population randomised (in days) · critically ill patients Interventions for preventing critical illness polyneuropathy and critical illness myopathy (2014) · Cochrane | no estimate extracted | 2 studies · 2748 participants | High |